Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 960-971

  Gerber, B ^a   Krause, A ^a   Muller H ^a   Richter, D ^a   Reimer, T ^a   Makovitzky, J ^a   Herrnring, C ^a   Jeschke, U ^a   Kundt, G ^a   Friese, K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN; UROKINASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW BIOPSY; BONE METASTASIS; BREAST CANCER; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL;

EID: 0035865153     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.960     Document Type: Article

References (85)

1. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking
2. Number of lymph nodes examined and the prognosis of breast carcinoma
3. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy
4. Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes
5. Cancer of the breast: The past decade (second of two parts)
6. Relation of tumor size. Lymph node status, and survival in 24,740 breast cancer cases
7. Long-term followup of breast cancer patients: The 30-year report
8. Polychemotherapy for early breast cancer: An overview of the randomized trials
9. Tamoxifen for early breast cancer: An overview of the randomised trials
10. The 1998 St. Gallen's Consensus Conference: An assessment
11. Detection and clinical importance of micrometastatic disease
12. Detection and clinical relevance of micrometastatic cancer cells
13. Meta-analyses of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated
14. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma
15. The significance of breast cancer lymph node micrometastases
16. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer
17. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis
18. Monoclonal antibody studies of mammalian epithelial keratins: A review
19. Intermediate filaments. Efficacy in surgical pathologic diagnosis
20. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17 monoclonal antibodies
21. Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow
22. Nonparametric estimation from incomplete observation
23. Evaluation of survival data and two new rank order statistics arising in its consideration
24. Regression model and life tables
25. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study
26. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
27. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
28. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
29. Micrometastases: Marker of metastatic potential or evidence of residual disease?
30. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
31. Multiple prognostic factors and outcome analysis in patients with cancer. Communication from the American Joint Committee on Cancer
32. The prognostic significance of marrow micrometastases in women with early breast cancer
33. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients
34. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis
35. Micrometastases in bone marrow in patients with primary breast cancer: Evaluation as an early predictor of bone metastases
36. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years follow-up
37. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study
38. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
39. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis
40. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
41. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients
42. Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis
43. Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
44. Prognostic significance of micrometastatic bone marrow involvement
45. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
46. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
47. Early metastasis of human solid tumours: Expression of cell adhesion molecules
48. Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells
49. Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11
50. Combined sentinel lymph-node mapping and bone-marrow micrometastatic analysis for improved staging in breast cancer
51. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
52. The size of a micrometastasis in the axilla in breast cancer: A study of nodal tumour-load related to prognosis
53. Effectiveness of multiple-level sectioning in detecting axillary nodal micrometastasis in breast cancer: A retrospective study with immunohistochemical analysis
54. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
55. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
56. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology
57. Micrometastases in breast cancer: Long-term follow-up of the first patient cohort
58. Detection of occult breast cancer micrometastases in axillary lymph nodes using a multimarker reverse transcriptase-polymerase chain reaction panel
59. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation
60. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis
61. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients
62. Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer
63. Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features
64. Sentinel node biopsy in breast cancer-a minimally invasive procedure for staging of the axilla
65. Pathologic examination of sentinel lymph nodes in breast cancer
66. Sentinel lymph node biopsy: Strategies for pathologic examination of the specimen
67. Sentinel lymphadenectomy in breast cancer: Identification of sentinel lymph node and detection of metastases
68. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging
69. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
70. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
71. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction
72. Molecular detection of minimal residual disease in colorectal and breast cancer
73. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification
74. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients
75. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction
76. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction
77. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer
78. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic disease in axillary lymph nodes of breast cancer patients
79. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
80. Limitations of reverse-transcriptase, polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow
81. The fate of bone marrow micrometastases in patients with primary breast cancer
82. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
83. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
84. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow
85. Edrecolomab (monoclonal antibody 17-1A)